Analysis of Foxp3− effector CD4+ T cells in both tumor models revealed that M002 treatment markedly increased the abundance of these cells expressing IFNγ and TNFα with peaks at day 14 and day 7 post-treatment in GSC005 or GL261-PVRL1 tumors, respectively, and also increased cells expressing Granzyme B (GzmB) at early time points (Fig. 2c, d and Supplementary Fig. 3f). This evidence concerns the gene FOXP3 and neoplasm.